Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dose-dense Doxorubicin/Cyclophosphamide With Intermittent Low-dose Sunitinib as Neoadjuvant or First-line Palliative Treatment of Newly Diagnosed HER2 Negative Breast Cancer Patients With Measurable Primary Breast Tumor

Next Previous
X
Search
Trial Profile

Dose-dense Doxorubicin/Cyclophosphamide With Intermittent Low-dose Sunitinib as Neoadjuvant or First-line Palliative Treatment of Newly Diagnosed HER2 Negative Breast Cancer Patients With Measurable Primary Breast Tumor

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 20 Jun 2022

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Bevacizumab (Primary) ; Sunitinib (Primary) ; Cyclophosphamide; Doxorubicin; Pegfilgrastim
  • Indications Breast cancer; Carcinoma; HER2 negative breast cancer
  • Focus Therapeutic Use

    • Most Recent Events

    • 14 Jun 2022 Results (n=34) evaluating dynamic changes in the molecular landscape of HER2-negative tumors treated with chemotherapy and anti-angiogenic agents published in the Targeted Oncology
    • 01 Feb 2022 Results published in the Breast Cancer Research and Treatment
    • 15 Jun 2016 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top